We are international
Donate
TEXT SIZE   


Understanding Ninlaro®

Ninlaro is the first oral proteasome inhibitor approved by the FDA to treat multiple myeloma. It is the third drug in the proteasome inhibitor class that has been approved for MM. Ninlaro is indicated for myeloma patients who have received at least one prior therapy. 

06.28.16


click here to view PDF

In November 2015, Ninlaro became the first oral proteasome inhibitor approved by the US Food and Drug Administration (FDA) to treat myeloma. Ninlaro is indicated for patients with myeloma who have received at least one prior therapy.

Proteasome inhibitors are a class of drugs. Proteasome inhibitors have been approved as an effective method of treating myeloma since 2003. Ninlaro is the third proteasome inhibitor approved for the treatment of myeloma, but it is the first oral proteasome inhibitor.

Ninlaro is taken in capsule form rather than as an intravenous drug that is administered at a clinic or doctor’s office. Currently, Ninlaro is approved by the FDA for use in combination with the immunomodulatory drug Revlimid® (lenalidomide) and dexamethasone (a corticosteroid). 


 related articles